Table 2.
Preliminary analyses for pooled SIR of incident CVD in HL and NHL survivors (using random‐effects models)
| Outcome (CVD subtype) | Hodgkin Lymphoma | Non‐Hodgkin's Lymphoma | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies | No. of estimates | Pooled SIR estimate | 95% CI | I 2 | 95% Prediction Interval | No. of studies | No. of estimates | Pooled SIR estimate | 95% CI | I 2 | 95% Prediction interval | |
| CBVD | 7 | 10 | 1.99 | 1.56‐2.55 | 90.3% | 0.81‐2.55 | 5 | 5 | 1.66 | 1.46‐1.88 | 0.0% | 1.35‐2.04 |
| CD | 4 | 6 | 3.23 | 2.23‐4.68 | 93.0% | 0.86‐12.17 | 2 | 4 | 1.96 | 1.22‐3.13 | 72.3% | 0.27‐14.36 |
| CHD | 11 | 19 | 2.54 | 1.95‐3.31 | 97.2% | 0.80‐8.11 | 4 | 6 | 1.14 | 0.95‐1.37 | 0.0% | 0.88‐1.48 |
| CVD | 6 | 6 | 2.37 | 1.43‐3.91 | 98.1% | 0.38‐14.76 | 3 | 3 | 1.90 | 1.43‐2.52 | 86.7% | 0.06‐57.39 |
| MD | 7 | 12 | 3.95 | 2.48‐6.27 | 97.1% | 0.64‐24.50 | 5 | 7 | 5.38 | 3.35‐8.64 | 89.8% | 1.02‐28.33 |
| PD | 3 | 3 | 10.67 | 7.75‐14.69 | 63.3% | 0.33‐343.56 | 1 | 1 | 4.70 | 2.08‐10.61 | ‐ | ‐ |
| VHD | 5 | 5 | 13.10 | 7.41‐23.16 | 96.2% | 1.50‐114.72 | 2 | 2 | 3.76 | 2.12‐6.66 | 51.5% | ‐ |
Abbreviations: CBVD, cerebrovascular disease; CD, cardiac dysrhythmia; CHD, coronary heart disease; CVD, any cardiovascular disease; MD, myocardial disease; PD, pericardial disease; VHD, valvular heart disease.